A. Gonzalez Martin - AI Profile | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 18 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

232P Identification of ‘secondary’ germline cancer predisposition variants from somatic tumour testing: Should we evolve towards universal screening

A. Gallego Martinez, T. Imizcoz, L. Sánchez-Lorenzo,M. Mora, D. Domínguez, A. Gurpide, J. Espinos Jimenez,J.M. Aramendia, A. Chopitea Ortega, M. Santisteban Eslava, M. Ponz-Sarvise, J.L. González,

Annals of Oncology (2023): S274-S274

引用0浏览0引用

795P Tolerability and effectiveness of niraparib in long-term responders with platinum-sensitive recurrent ovarian cancer (GEICO-88R study)

J.F. Cueva Banuelos, C. Salvador Coloma, F. Galvez Montosa, J. Ferreiro Quintana,S. Cros Costa, S. González-Santiago, J.G. Cassinello,M. Romeo Marin, P. Reche, M.L. Soriano Tabares,M. Valero Arbizu,M.J. Rubio Perez,

Annals of Oncology (2023): S533-S533

引用0浏览0引用

InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator's choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

K. Fujiwara, B. M. Slomovitz,A. Gonzalez Martin, E. Kalbacher, A. Bagameri, S. Ghamande,J-Y. Lee, S. Banerjee, F. C. Maluf, D. Lorusso, K. Yonemori,E. van Nieuwenhuysen,

ANNALS OF ONCOLOGY（2023）

引用0浏览0引用

33O PRIMA/ENGOT-OV26/GOG-3012 study: Long-term conditional PFS

A.J. Gonzalez Martin,B. Pothuri,I.B. Vergote, W. Graybill,M.R. Mirza, C. McCormick, D. Lorusso,G. Freyer,F. Backes,F. Heitz,A. Redondo Sanchez, R. Moore,

ESMO Open（2023）

引用1浏览0引用

741MO Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), demonstrates clinical activity in recurrent/progressive epithelial endometrial cancer (EEC): STRO-002-GM1 phase I dose expansion

B. Pothuri,R.W. Naumann,L.P. Martin, D. O'Malley, D. Uyar, J.W. Moroney,J. Diaz, J. Garcia-Donas,A. Redondo Sanchez,A. Gonzalez Martin, D.G. Illescas, L. Liu,

Annals of Oncology (2023): S508-S508

引用0浏览0引用

818TiP REFRaME-O1/ENGOT-OV79/GOG-3086: A phase II/III open-label study evaluating the efficacy and safety of luveltamab tazevibulin versus investigator’s choice of chemotherapy in women with relapsed platinum-resistant epithelial ovarian cancer expressing folate receptor alpha (FolRα)

R.W. Naumann,A. Gonzalez Martin, T.J. Herzog, R.L. Coleman, I.L. Ray-Coquard, R. Miller, L. Lu, H. Dokainish, C. Berman, A. Oaknin

Annals of Oncology (2023): S540-S541

引用0浏览0引用

LBA37 Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial

A. Gonzalez Martin,M.J. Rubio Perez, F. Heitz, R.D. Christensen,N. Colombo,T. Van Gorp, A. Oaknin, A. Leary,L. Gaba Garcia, C. Lebreton,L.M. De Sande González,M. Romeo Marin,

Annals of Oncology (2023): S1278-S1279

引用0浏览0引用

770P Tolerability and efficacy of trabectedin plus pegylated liposomal doxorubicin (PLD) in elderly patients with ovarian cancer (OC): GEICO 105-O study

M.J. Rubio Perez,A. Manzano Fernández,L.M. De Sande González,P. Estevez Garcia, M.D.M. Gordon Santiago, D. Soto de Prado, B.A. Hernando Fernandez,E.M. Guerra Alia, A. Carbo Bague,I. Romero, M. Corbellas Aparicio, A. Gonzalez-Haba Martinez,

Annals of Oncology (2023): S523-S523

引用0浏览0引用

Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial

P. DiSilvestro,S. Banerjee,N. Colombo,G. Scambia,B-G. Kim, A. Oaknin,M. L. Friedlander, A. S. Lisyanskaya, A. Floquet,A. Leary, G. S. Sonke,C. Gourley,

Annals of Oncologyno. 7 (2022): S779-S779

引用5浏览0引用

530P PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety

A.J. Gonzalez Martin, B. Pothuri, I.B. Vergote, W. Graybill, M.R. Mirza, C. Mccormick, D. Lorusso, G. Freyer, F. Backes, K.H. Baumann,A. Redondo Sanchez, R.G. Moore,

Annals of Oncology (2022): S789-S789

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn